Clinical trials on drug repositioning for COVID-19 treatment
The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were reported. Coronavirus is an enveloped RNA virus, from the genus Betacoronavirus, that is dis...
Saved in:
Main Authors: | Sandro G. Viveiros Rosa (Author), Wilson C. Santos (Author) |
---|---|
Format: | Book |
Published: |
Pan American Health Organization,
2020-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus
by: Josidel Conceição Oliver, et al.
Published: (2022) -
Repositioning of Hypoglycemic Drug Linagliptin for Cancer Treatment
by: Yong Li, et al.
Published: (2020) -
Repositioning Chromones for Early Anti-inflammatory Treatment of COVID-19
by: Piero Sestili, et al.
Published: (2020) -
Changing Trends in Computational Drug Repositioning
by: Jaswanth K. Yella, et al.
Published: (2018) -
Drug Repositioning in Glioblastoma: A Pathway Perspective
by: Sze Kiat Tan, et al.
Published: (2018)